The 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium was a huge success! We produced more than 20 interviews on topics ranging from the BOLERO-2 and CLEOPATRA trials (Jose Baselga) to medical economics (Eric Winer), breast cancer and the environment (Robert Hiatt), the treatment of young women with breast cancer (Ann Partridge), metastatic breast cancer [...]

  Dr. C. Kent Osborne, the co-director of the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), discusses breast cancer advances and treatment highlights over the past year. He highlights three areas which he thinks will be practice changing: the overall treatment of HER2-positive breast cancer, the findings from the BOLERO-2 trial and the use of [...]

  Dr. Jose Baselga discusses the exciting data for the HER2-negative breast cancer patient — the BOLERO-2 trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard [...]

  Dr. Jose Baselga discusses the exciting data for the HER2-positive breast cancer patient — the CLEOPATRA trial released at the CTRC-AACR 34th Annual San Antonio Breast Cancer Symposium. Dr. Baselga is the Chief of the Division of Hematology/Oncology, Associate Director of the Massachusetts General Hospital Cancer Center and a Professor, Department of Medicine, Harvard [...]

  Dr. Eric Winer presented one of the plenary sessions at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. His talk was on endocrine therapy and looking into the future. His prognosis asks the question: Why haven’t we done better? And he addresses, what he believes, are the three key issues. Dr. Winer is [...]

  Dr. Eric Winer moderated a panel at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium focusing on medical economics and the cost of cancer care. How do we begin to address these issues? Dr. Winer is Chief of Women’s Cancers at Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. [...]

  Dr. Robert A. Hiatt discusses the Institute of Medicine Report on Breast Cancer and the Environment: A Life-Course Approach, presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. The report urges a life-course approach to studying breast cancer because new information suggests that women and girls might be more susceptible to some [...]

Dr. Julie R. Gralow discusses the SWOG SO226 where postmenopausal women with metastatic breast cancer given first-line treatment of fulvestrant (Faslodex) and anastrozole (Arimidix) have a better progression-free survival (PFS) than those given anastrozole alone. She also gives an update on bisphosphonates and osteonecrosis of the jaw at the 34th Annual CTRC-AACR San Antonio Breast [...]

  Dr. Clifford Hudis discusses what’s new with chemotherapy trials at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. He reviews eight posters from the conference that explored various chemotherapy-related questions. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan Kettering Cancer Center and Professor of Medicine at Weill-Cornell Medical College [...]

  Dr. Clifford Hudis, through his discussion of the trial showing bevacizumab (Avastin) slows metastatic breast cancer, he highlights the important topic of the value of progression-free survival (PFS). This interview was conducted at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium. Dr. Hudis is the Chief, Breast Cancer Medicine Service at Memorial Sloan [...]